COPENHAGEN, OCTOBER 26, 2015 – AntibioTx has been rewarded grant funding from The Innovation Fund Denmark to further develop a candidate developed on the basis of extensive compound screening models. The candidate is being developed for microbiome-related disorders in atopic dermatitis and the grant funding will be used to conduct IND-enabling safety studies as well as clinical Phase 1 and Phase 2 studies in patients suffering from atopic dermatitis.
Rasmus Toft-Kehler, CEO of AntibioTx, commented; “The reward of this grant enables AntibioTx to take candidates identified through our screening efforts into the clinic. This denotes a key milestone for a biotech company and allows us to verify the pre-clinical profile of our candidate as a new treatment alternative for atopic dermatitis patients. We are grateful for the support and trust from the Innovation Fund Denmark and look forward to initiating the studies”.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.